Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q4 FY2019 Earnings Presentation
23 slides from Eris Lifesciences's earnings presentation, May 21, 2019
Slide 1: Exchange filing cover letter: Investor Presentation
Date: May 21, 2019 To To The Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai- 400001 Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear
Slide 2: Eris Lifesciences Ltd Q4 19 and FY 19 Investor Presentation
ERIS LIFESCIENCES LTD Q4 19 and FY 19 INVESTOR PRESENTATION 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 4: FY 19 – Business Highlights
FY 19 – BUSINESS HIGHLIGHTS • Strong Growth Momentum Regained • Substantial yoy growth in H2 19 (16.7% vs 9.9% for IPM) after slower growth in H1 19 (2.4% vs 9.3% for IPM) * • High Q4 19 yoy growth 22.3% vs 9.9% for IPM * • Business more chronic in nature than ever – 85% of FY 19 sales from chronic
Slide 5: FY 19 – Financial Highlights
FY 19 – FINANCIAL HIGHLIGHTS • Acquired additional 6.71% of Kinedex Healthcare Private Ltd in FY 19. In April 2019 acquired balance holding making it a wholly owned subsidiary • In April 2019 prepaid entire term loan achieving debt free status 4
Slide 6: Patient Centricity – Our Core DNA
PATIENT CENTRICITY – OUR CORE DNA IMPROVING HEALTH OUTCOMES PATIENT CARE INITIATIVES Identifying and addressing gaps in the healthcare delivery ecosystem to improve health outcomes 59,000 ABPMs 1,24,000 50,000 Office and Home 9,200 CGM conducted 1,00,000 30,000 Holter on Calls Patients screened Bloo
Slide 7: What's New at Eris
WHAT’S NEW AT ERIS Financial Express CFO of the First of Its Kind Initiative in India National Best Employer Year Awards 2019 World’s first Smart Continuous Glucose Brand 2018 Eris wins in the Medium Enterprises Monitoring System - Guardian Connect Eris wins out of 100 brands (Manufacturing Industry
Slide 8: Q4 19 Eris Lifesciences
Q4 19 Lifesciences
Slide 9: Q4 19 – Income Statement
Q4 19 – INCOME STATEMENT Consolidated Q4 19 Q4 19 Q4 18 INR mn yoy GR Sale of Products 2,111 2,081 1.5% Other Operating Income 37 41 Subdued Sales in Q4 19 due to inventory Revenue from Operations 2,148 2,122 1.2% rationalisation at stockists Gross Profit 1,799 1,792 0.4% Gross Profit Margins 83.8%
Slide 10: Q4 19 – Entity Wise Sales
Q4 19 – ENTITY WISE SALES Consolidated Q4 19 Sale of Products Q4 19 Q4 18 Q4 19 Q4 19 Q4 18 INR mn yoy GR INR mn yoy GR Sale of Products 2,111 2,081 1.5% Consolidated 2,111 2,081 1.5% Other Operating Income 37 41 Revenue from Operations 2,148 2,122 1.2% Gross Profit 1,799 1,792 0.4% Stand alone 1,94
Slide 11: Q4 19 – Business More Chronic Than Ever
Q4 19 – BUSINESS MORE CHRONIC THAN EVER Consolidated Q4 19 Sale of Products Q4 19 Q4 18 Q4 19 Q4 19 Q4 18 INR mn yoy GR INR mn yoy GR Sale of Products 2,111 2,081 1.5% Consolidated 100% 2,111 2,081 1.5% Other Operating Income 37 41 Revenue from Operations 2,148 2,122 1.2% Chronic + Sub Chronic Gross
Slide 12: Q4 19 – Substantial Secondary Growth
Q4 19 – SUBSTANTIAL SECONDARY GROWTH Q4 19 yoy GR Total 22.3% 9.9% Eris IPM Chronic + Sub Chronic Therapies Acute Therapies 23.9% 12.5% 14.7% 6.9% Eris IPM Eris IPM THERAPY WISE SALES GROWTH TRENDS Source: AIOCD Mar’19 11
Slide 13: Q4 19 – Prescriptions Growth Trends
Q4 19 - PRESCRIPTIONS GROWTH TRENDS Prescription Ranking* 3 3 4 CARDIOLOGY DIABETOLOGY GASTRO 3 7 CONSULTING NEUROLOGY PHYSICIAN Source: SMSRC Feb’19 * Rx Rank in Represented Market (Rx Jan-Feb’19) 12
Slide 14: FY 19 Eris Lifesciences
FY 19 Lifesciences
Slide 15: FY 19 – Income Statement
FY 19 – INCOME STATEMENT Consolidated FY 19 FY 18 FY 19 yoy Gr INR mn Sale of Products 9,672 8,271 16.9% Other Operating Income 150 285 Revenue from Operations 9,822 8,556 14.8% Gross Profit 8,285 7,215 14.8% Gross Profit Margins 84.4% 84.3% Employee cost 1,907 1,573 21.2% as % of Revenue 19.4% 18.4
Slide 16: FY 19 – Entity Wise Sales
FY 19 – ENTITY WISE SALES Consolidated Sale of Products FY 19 FY 19 FY 18 FY 19 yoy Gr INR mn FY 19 FY 18 yoy GR INR mn Sale of Products 9,672 8,271 16.9% Consolidated 9,672 8,271 16.9% Other Operating Income 150 285 Revenue from Operations 9,822 8,556 14.8% Gross Profit 8,285 7,215 14.8% Stand alon
Slide 17: FY 19 – Business More Chronic Than Ever
FY 19 – BUSINESS MORE CHRONIC THAN EVER Consolidated Sale of Products FY 19 FY 19 FY 18 FY 19 yoy Gr INR mn FY 19 FY 18 yoy GR INR mn Sale of Products 9,672 8,271 16.9% Consolidated 100% 9,672 8,271 16.9% Other Operating Income 150 285 Revenue from Operations 9,822 8,556 14.8% Chronic + Sub Chronic
Slide 18: H1 and H2 19 – Substantial Secondary yoy Growth in H2
H1 and H2 19 – SUBSTANTIAL SECONDARY yoy GR in H2 19 Total ERIS IPM 16.7% 9.3% 9.9% 2.4% H1 19 H2 19 Chronic + Sub Chronic Therapies Acute Therapies 19.6% 10.8% 12.2% 5.4% 7.7% 7.2% 3.7% -10.9% H1 19 H2 19 H1 19 H2 19 THERAPY WISE SALES GROWTH TRENDS Source: AIOCD Mar’19 17
Slide 19: FY 19 – Prescriptions Growth Trends
FY 19 – PRESCRIPTIONS GROWTH TRENDS Prescription Ranking* 4 3 3 CARDIOLOGY DIABETOLOGY GASTRO 4 6 CONSULTING NEUROLOGY PHYSICIAN Source: SMSRC Feb’19 * Rx Rank in Represented Market (Rx MAT Feb’19) 18
Slide 20: FY 19 – Eris Rank Progression & Brand Health
FY 19 – ERIS RANK PROGRESSION & BRAND HEALTH Top 10 Mother Brands contribute 63% to total sales Rank Progression Market Share Sales Val FY 19 Brand Market Brand FY 19 (INR Mn) Growth Growth Rank 2019 24 TOP 10 Total 6.0% 7,736 14.6% 13.1% --- GLIMISAVE 5.8% 2,212 13.1% 11.5% 6 29 2017 ERITEL 5.1% 1,
Slide 21: FY 19 – Key Metrics
FY 19 – KEY METRICS YPM MRs Medical & Shareholding Pattern as on 31 Mar 19 Lacs per month Research Team 7.32% 0.98% 4.1 2,000 40 11.75% CFAs Stockists Retail chemists 5,00,000+ 56.10% 1,950 + 23.86% 23 Promoter Public MF FPI Other Source: Internal Numbers 20
Slide 22: FY 15 – FY 19 Key Performance Indicators
FY 15 – FY 19 KEY PERFORMANCE INDICATORS Revenue From Operation Operating EBITDA Profit After Tax 3,449 2,950 2,911 9,822 3,220 8,556 2,691 2,467 7,495 6,148 1,715 5,545 1,336 1,215 892 FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY 19 Operating Cash Flow Retu
Slide 23: Thank You
THANK YOU Lifesciences